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Abstract: In the search for an effective strategy to overcome antimicrobial resistance, a series of 
new morpholine-containing 5-arylideneimidazolones differing within either the amine moiety or at 
position five of imidazolones was explored as potential antibiotic adjuvants against Gram-positive 
and Gram-negative bacteria. Compounds (7-23) were tested for oxacillin adjuvant properties in 
the Methicillin-susceptible S. aureus (MSSA) strain ATCC 25923 and Methicillin-resistant S. aureus 
MRSA 19449. Compounds 14-16 were tested additionally in combination with various antibiotics. 
Molecular modelling was performed to assess potential mechanism of action. Microdilution and 
real-time efflux (RTE) assays were carried out in strains of K. aerogenes to determine the potential 
of compounds 7-23 to block the multidrug efflux pump AcrAB-TolC. Drug-like properties were 
determined experimentally. Two compounds (10, 15) containing non-condensed aromatic rings, 
significantly reduced oxacillin MICs in MRSA 19449, while 15 additionally enhanced the effectiveness 
of ampicillin. Results of molecular modelling confirmed the interaction with the allosteric site of 
PBP2a as a probable MDR-reversing mechanism. In RTE, the compounds inhibited AcrAB-TolC even 
to 90% (19). The 4-phenylbenzylidene derivative (15) demonstrated significant MDR-reversal "dual 
action" for ß-lactam antibiotics in MRSA and inhibited AcrAB-TolC in K. aerogenes. 15 displayed also 
satisfied solubility and safety towards CYP3A4 in vitro.
Keywords: 5-arylideneimidazolones; multidrug resistance; antibiotic adjuvant; Staphylococcus aureus; 
MRSA; Klebsiella aerogenes; PBP2a; AcrAB-TolC; molecular docking; RTE assay
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1. Introduction
1.1. Bacterial M ultidrug Resistance
The discovery of the first antibiotic by  A lexander Flem ing in 1928 w as a great break­
through in  the treatm ent of bacterial infectious diseases. R ather unexpectedly, bacterial 
infections revived to becom e a global threat once again due to the em ergence, spread and 
persistence of m ultidrug resistant (M DR) bacteria all over the w orld [1- 4] . M D R  bacteria 
have caused already a few epidem ics and this problem  is increasing rapidly [5 ]. Although 
this issue has raised a lot of attention in recent years, all policies and incentives that have 
been proposed to com bat M D R  brought only a little progress yet, and the current lack of 
solutions is likely  to exert m ajor consequences on our healthcare system  and m ay also 
affect social and econom ic fields [6]. Thus, it is crucial to search for new  antim icrobial 
drugs or other strategies able to overcom e M D R  [2,4,7 ,8] . Such strategies include, for 
instance, the use of antibodies, bacteriophages, and antibiotic ad juvant therapy [9,10]. In 
this context, the developm ent of adjuvant m olecules able to restore antibacterial activity of 
marketed antibiotics is an attractive strategy [10- 12]. The great efficacy of chemosensitizers 
is related to inhibition of various mechanism s of bacterial resistance e.g., perm eation across 
outer mem brane, efflux pumps, m odification of drug target, and enzym atic inactivation of 
drugs [8,10].
1.2. AcrAB-TolC Efflux Pump
A m ong bacterial defense strategies, active efflux is a w idespread and sim ple m echa­
nism  contributing to the first line of bacterial defense [6] . M em brane transport proteins, 
e.g., efflux pum ps, can extrude intracellularly acting antibiotics but also m any other struc­
turally  d iverse substances, e.g., toxins, b ile salts, dyes, detergents, and organic solvents. 
M oreover, they are one of the m ajor contributors to clinical M D R  in G ram -positive and 
G ram -negative bacteria [13- 16]. The tripartite system  A crA B-TolC, a m em ber of the 
R esistance-N odulation-C ell D ivision (RN D ) family, is one of the m ost im portant efflux 
pumps utilized by Gram -negative M D R bacteria, w hich confers resistance to a broad range 
of antibiotics, such as ß-lactam s, fluoroquinolones, m acrolides, and tetracyclines [13]. This 
pum p is com posed of the follow ing proteins: a transport protein located in  the inner 
m em brane (A crB), a m em brane fusion protein (A crA ), and an outer m em brane protein 
(TolC) [14], w hich  form  a com plex able to export intracellu larly  localized cargo into the 
extracellular milieu via an electrochemical gradient [13]. Antibiotic adjuvants able to block 
efflux-m ediated m echanism s of resistance are called efflux pum p inhibitors (EPIs) [10]. 
Richter et al. pointed out that potential EPIs, which probably accumulate in Gram-negative 
bacteria, should (i) possess an amine (preferably primary amine), (ii) be amphiphilic, (iii) be 
rigid, and (iv) possess low globularity [17].
1.3. Penicillin Binding Protein (PBP)
In the group of Gram -positive bacteria, m ultidrug-resistant variants of Staphylococcus 
aureus are of m ajor concern. The bacterium  is responsible for a wide range of infections [18]. 
This ability is connected to various virulence factors, e.g., enzym es and toxins [18]. N ow a­
days, S. aureus is one of the "superbugs" due to the acquisition of multiple resistance deter­
m inants, and a lot of attention is drawn to m ethicillin-resistant S. aureus (MRSA) [4,18,19]. 
M RSA  harbors a m obile genetic elem ent called staphylococcal cassette chrom osom e mec 
(SCC m ec) w ith in  their chrom osom e, w hich  includes am ong others the genes m ecA  or 
m ecC, encoding for an alternative penicillin  binding protein, PBP2a, w hich  has reduced 
affinity for ß-lactam  antibiotics [8,20].
PBP and its modification PBP2a are enzymes which bind to bacterial membrane. They 
catalyze transpeptidation and transglycosylation reactions, w hich  are necessary during 
bacterial cell w all biosynthesis [21,22]. D ue to the change in alternative PBP2a, ß-lactam  
antibiotics are not able to block this reaction [21,22]. Hovewer, ceftaroline, w hich belongs 
to ß-lactam  antibiotics, show s an activity even in M RSA  strains [21]. This interesting fact 
w as explained due to crystallographic studies of PBP2a, w hich, apart from  the active site,
indicated presence of an allosteric one in non-penicillin-binding domain [21,22]. Moreover, 
O tello et al. pointed out that an incorporation of a com pound to allosteric site changed 
the active site into open conform ation, w hich led to restoration of ß-lactam  antibiotics 
actibity [21].
1.4. Potency o f  Im idazolones in Battle against Bacterial M D R
Notably, our previous studies proved that im idazolones and hydantoins displayed 
significant activities as antibiotic ad juvanis in botb , Gram -pouitive and G ram -negative, 
M D R  bacteria. A rylideneim id azolones w ith  unsubstituted piperazine at position 2 w ere 
highly active as EPis of the AcrAB-TolC pum p in M DR strains oi E. coli (1 and 2, Figure 1) 
duriog  the real-tim e efflux (ROE) assays. Based on resulds in  m icrodilution assays, a 
presence of non-condensed rings, i.e., b iphenyl, in  com parison  to condensed ones, i.e., 
flnorene (1 vs. 2, Figure 1), significantly affected abilities of m olecules tec increase efficacy 
of more diverse antibiotics. Com pounds 1 and 2 w ere promising, although they displayed 
cytotoxicity  in hum an liver carcinom o cells; (H epG 2) at concentrations required for ad­
juvant activity  assays. These results pointed out a need for further m odifications in the 
arylideneim idazolone group [23].
Figure 1. The previously found 5-arylideneimidazolones able to block AcrAB-TolC efflux pump 
(1, 2) [23].
Thus, next studies induded m odifications of either aromatic nr amine fragments. The 
am ine m oieties w ere chosen on ahe basic of already described active adjuvants, w hich 
poeseyspd either m ethylpiperazine, e.g., N M P (3, Figure 2 ) or m orpholine fragm ent, e.g., 
M BX 2319 and BG1167 (4 and 5, Figure 2) [24- 26]. Moreover, linker between the amine and 
im idazolone core w as im plem anted. Crystallographic analysis tor the chlorobenzylidene 
derivative (6, bigure 2) showed that Di-m oth rearrangem eni gurprisingly modified the sub- 
stitoenta topulogy, aed thus, methylpiperazine was; connected by linker to the imidazolone 
cote a t position 3 [27]. Tire studies indicated an ability of the new  im idazolones to block 
different M D R  m echanism s in both, G ram  positive and G ram  negative, bacteria. They 
pointed out thap two com poundr possessing; m orpholine instead of the m ethylpiperazine 
m oiety w ere even m ore potent (oxacillin adjuvants in the M RSA strain investigated. In the 
case of M DR Klebsiella aerogenes (Enterobacter aerogenes in our previous papers), those series 
<if com pounds did not potentiate antibiotics effectiveness, but Uemonstrated EPI action in 
ihe real-time efflux (RTE) Tssays usinu tire strein w ith overexpression of AcrAB-TolC efflux 
pum p [27].
Those interesting results, but limited for only two m orpholine-im idazolone representa­
tives tested in only one M RSA strain (MRSA H EM SA 5), distinctly indicated a strong need 
of further extended studies in this chemical group, including both, w ider chemical m odifi­
cations and greater variety  of M D R  strains involving additional antibiotics. Furtherm ore, 
"d ru gability" questions should have been taken into account.
BG-1167
Figure 2. Previously identified antibiotic adjuvants containing: methylpiperazine i.e., NMP (3) or 
morpholine i.e., MBX2319, BG1107 (4 and 5, respectively) as well as active oxacillin chemosensitizer 
fronr 5-arylideneimidazolones (6) [24- 27].
1.5. Research Purpose and Scope
In cesponse to the aforem entioned challengas, and electing tw o previous ly found 
com pounds (1 and 6, Figures 1 and 2, respectively) as lead structures, w e decided to 
com plete a series of m orpholine-im idazolones, including a few m em bers found before, in 
order to investigate the role of topological variety w ithin this chemical group for reversing 
bacterial MDR. For this purpose, the following modifications within respective areas of the 
lead structures (1 and 6) have been arranged: (i) the arom atic m oiety at position 5, (ii) an 
exchange of piperazine (at posiOion 2 or 3, respectively) into m orpholine, (iii) modifications 
wiOhin the linker between the m orpholine and im idazol one, (iv) an exchange of im idszolone 
core into thiazolone one (Figure 3 ).
R: bulky arom atic  substituents 
o f (un)fused rings
X: N, s n:0 ,l
Leads modifications
Figure 3. Lead structures (1 and 6) and their modificaOions performed within this study? [23,27].
Thus, a series of new 5-arylideneim idazolones (7-21, groups A and B) or 5-arylidene- 
thiazolones (22 and 23, group C) containing the m orpholine m otive either a t position  2 
(group A  and C) or a t position 3 (group B), w as investigated w ithin  this study (Tables 1 
and 2 ). Synthesis of new  com pounds and crystallographic studies for one representative 
(7) were performed. Antibiotic adjuvant properties for com pounds 7-23  were evaluated in 
comprehensOve m icrobiological assaye, including tests in M D R G ram -positive and G ram ­
negative strains. C hosen com pounds w ere tested in extended screening w ith  a panel of
R1: NH2, m orpho line,
R2:
Lead 1 Lead 6
NH2
antibiotics and various clin ically  derived S. aureus strains. In  order to test their im pact 
on G ram -negative bacteria, com pounds w ere exam ined foa their EPI activity  in A crA B- 
TolC expressing K. aerogenes in RTE . N ext, m olecular m odellina studies w ere peoformed 
to determ ine probvble m echanism e oC the ad juvant aceion. For selected com pounds, 
"dru glikeneos" w as exam ined, Le., w aler solubüity  as w ell as chem iccl and m etabolic 
stability and potentinl dcugedrug interactions (DDI) usinv l̂ n̂ -tl̂  in sihco and oxparimental 
ansays. Finally, tire structure-activity relationship (SAR) hes been antlyzed.
Table 1. General structure and modificationr ot gsoupA (7-I3(.
Group A
7 8-13
Table 2. General structures and modifications of group B and C (14—23).
Group B Group C
14-21 22 , 23
Cpd Group R n Cpd Group R n R1
2. R esu lts and D iscu ssion
2.1. Synthesis
The routes for the synthesis of im idazolone (7-21) and thiazolone (22, 23) derivatives 
are depicted in  Schem e 1, w hile the synthesis of com pounds 7-10 , 12-17 , 19-21 , 24—30, 
32 -38  has been  described elsew here [27,28]. In the first step, K noevenagel condensation 
w as perform ed, in w hich im idazolidinone or thiazolidinone reacted w ith  an appropriate 
aromatic aldehyde to access the interm ediates, namely 5-arylideneim idazolidinones (24-30,
Schem e 1) or 5-arylidenethiazolidinone (31, Schem e 1). These com pounds (24-31) w ere 
S-m ethylated to obtain further interm ediates (32-39). Then, the S-m ethyl group at position 
2 w as replaced by  m orpholine-containing am ine m oieties (7 -13 , 22 group A  and C) or 
prim ary am ine ( 1 ( 2 1 ,2 3  group B and C) via the reactionbetw een com pounds 32-39  and 
com m ercially  available prim ary or secondary am ines. W hen  the prim ary am ines w ere 
em ployed in  the reaction w ith  im idazolone derivatives (32-38), D im roth rearrangem ent 
w as observed [27].
Scheme 1. Route of synthesis for arylideneimidazolones (7-21 ; group A and I1) and arylidenethia- 
zolones (22, 23; group C): (i) appropriate aldehyde, CH^COONa, CH3COOH, reflux, 5 -7  h, then rt, 
20 h; (ii) CH3 I, EtONa, rt, 24 h; (iii) appropriate amine, 120-130 °C, 15 min, then EtOH, reflux, 5-6 h, 
then rt, 20 h; (iv) Dimroth rearrangement.
2.2. X-ray Crystallography
In order to determine the structural properties of this interesting group of m orpholine- 
im idazolones, crystallographic analysis for com pound 7 w as perform ed. The m olecular 
structure and atom  num bering schem e are show n in Figure 4 . In the crystal structure 
presented, the asym m etric u nit consists of one cation being the protonated com pound 
7 at N1 atom , one chlorine anion and three w ater m olecules. M olecule 7 possesses Z 
configuration at the C 5=C 6 double bond. We have observed the sam e atomic arrangem ent
at the double bond also in other crystal structures of 5-arylideneim idazolone derivatives 
determ ined earlier [29,30]. The 5-arylideneim idazolone fragm ent is alm ost planar w ith  a 
dihedral angle of 8.6 7° betw een both  rings. The angle betw een the planes of the im ida- 
zolone and the second arom atic ring is 10.28°. The m orpholine ring; a t C2 adopts chair 
conform ation w ith  the interm ediate location of tine substituent fit N2 betw een equatorial 
and axial position. The torsion ang.e C 2-N 2-C19-C20 is 134.39°. The protonated N1 atom 
is engaged in a rharge-asiisted  hydrogen bond w ith  the w ater m olecule O1W. It is w orth 
noting that a learch  of ehg C am bridge Structural D ataba se (CSD ) [ 31] for the protonated 
5-arylideneim idazolone ring containing a N  atom  at (32 atom  resulted only in one crystal 
structure [ea]. The hydrognn bonding pattern presented an-  involving; a protonated hy­
drogen atom , three w ater m elecules and chlorine anion  is very  seldom  observed in the 
C SD  (31]. The packing of m olecules in  the crystal is dom inated by  N -H  - O, O -H  -Cl, 
O -H  -O and C-H- -O in term olead ar hydrogen b rn d s (Figure 5), w hose param eters are 
listed in Table n
Figung 4. The molecular structure of protonate- molecule 7 with the atom numbering scheme. 
Displenement ellipsoids are drawnat the 50% probability level. Orange dashed lines show hydrogen 
bionds betwenn the chloride anion, three water molecules and protonated N1 atom.
Figure 5. The intermolecular interactions of 7 in the crystal. Purple dashed lines indicate hydro­
gen bonds.
Table 3. Parameters of intermolecular hydrogen bonds.
D - H - A H---A(A) D---A(A) D-H-A (°) Symmetry Code
N1-H1N---O1W 2.00(2) 2.875(1) 173(2)
O1W-H1WA---O2W 2.09(3) 2.921(2) 170(2)
O2W-H2WB---O3W 1.93(2) 2.712(2) 174(2)
O3W-H3WA- ■ -Cl1 2.44(3) 3.239(1) 167(2)
N3-H3N---O2W 2.01(2) 2.857(2) 173(2) x, —y+1/ 2, z+1/2
O1W-H1WB- ■ ■ Cl1 2.50(3) 3.334(1) 174(2) —x+1, y+1/ 2, —z+1/2
O2W-H2WA- ■ -Cl1 2.41(2) 3.206(1) 170(2) —x+1, y—1/ 2, —z+1/2
O3W-H2WB- ■ ■ Cl1 2.39(3) 3.203(1) 162(2) —x+1, y+1/ 2, —z+1/2
C21-H21B---O1W 2.43 3.136(2) 127.5
C6-H6---O4 2.46 3.151(2) 129.1 —x, —y +1, —z+1
C19-H19A---O2W 2.45 3.433(2) 170.0 x, —y+1/ 2, z+1/2
C19-H19B-O1 2.32 3.283(2) 163.8 —x+1, —y, —z+1
C20-H20A---Cl1 2.90 3.845(1) 159.5 x, —y+1/ 2, z+1/2
C20-H20B---O1 2.65 3.295(2) 122.7 —x+1, —y, —z+1
C21-H21A---Cl1 2.96 3.879(1) 155.0 —x+1, y+1/ 2, —z+1/2
2.3. Biological Screening in S. aureus
In terms to assess the potential adjuvant activity of compounds (7-23) in Gram-positive 
bacteria, m icrobiological assays w ith  S . aureus  strains w ere perform ed. In these studies, 
d ifferent M SSA , M RSA  and V ancom ycin-interm ediate S. aureus (VISA ) w ere used. The 
adjuvant effect of com pounds w as evaluated in com bination w ith  several antibiotics, i.e., 
oxacillin, ampicillin, vancom ycin, ciprofloxacin and erythromycin. Compounds (7-23) were 
exam ined in com bination w ith oxacillin in M SSA isolate ATCC 25923 and the M D R isolate 
M R SA  19449. Selected 5-arylideneim idazolones (14-16) w ere investigated additionally  
w ith  a panel of antibiotics in  tw o M SSA  and eight M RSA  strains. M oreover, potential 
m echanism s of action for the series w ere determ ined em ploying docking and m olecular 
dynam ics sim ulation w ith both, active and allosteric, sites of PBP2a.
2.3.1. A ntibacterial A ctivity in S. aureus
The intrinsic antibacterial activity of the seventeen 5-arylideneim idazolone derivatives 
w as assessed by determ ining their m inim al inhibitory concentration (M IC) values in 
ATCC 25923 and M RSA  19449. Results are presented in  Supplem entary (Table S1). The 
results indicated that none of 5-arylideneim idazolones analyzed displayed a therapeutically 
relevant stand-alone antistaphylococcal activity. The M IC values of compounds 7 -1 7 ,1 9 -2 3  
w ere in the range of 0.03125 -  0.25 m M  against both  S. aureus  strains w ith  the exception 
of com pound 18, w hich  displayed even higher M ICs of 1 m M  and 2 m M  in ATCC 25923 
and M RSA  19449, respectively. Results for com pounds 16 and 20 in ATCC 25923 strain 
w ere published previously [27]. These findings suggest that the com pounds are not likely 
to becom e antibiotics by  them selves, and thus are unlikely  to elicit antibiotic resistance 
formation w hen added as an adjuvant molecule. N onetheless, for a num ber of compounds, 
precipitation w as observed after the addition of bacterial suspension in  M H  II broth  
(compounds 8,1 0 ,1 5 -1 8 , and 22), and thus, reported M ICs for these compounds should be 
interpreted w ith caution.
2.3.2. A djuvant Effects for Oxacillin
Given the lack of a clear antistaphylococcal activity of any of the 5-arylideneimidazolones 
and 5 -arylidenethiazolones tested here, we next tested their chemosensitizing capabilities in 
com bination w ith the penicillinase-resistant ß-lactam  antibiotic oxacillin. For this purpose, 
com pounds 7 -23  at a concentration of 1 /4  of their M ICs w ere added to tw o-fold  serial 
dilutions of oxacillin. M oreover, the effectiveness of the antibiotic alone w as tested, w hich 
yielded M ICs of 0.25 p g /m L  for ATCC 25923 and 256 p g /m L  for M RSA 19449. Potentiating 
effects of com pounds w ere then determ ined by  com parison of the efficacy of oxacillin  
tested in the presence and absence of compounds and expressed as activity gain A (Table 4 ).
D etailed results for the w hole series are show n in Supplem entary (Table S2). A m ong the 
series of compounds tested, two derivatives, compounds 10 and 15, significantly enhanced 
the efficacy of oxacillin against M RSA strain 19449 (Table 4, Supplem entary Table S2). W hen 
supplem ented at a concentration of 0.0625 mM , com pound 10 reduced oxacillin resistance 
of M RSA  19449 by  four- to eight-fold . A  slightly  low er activity  gain  w as determ ined 
for com pound 15, w hich  once added at a concentration of 0.0625 m M , decreased the 
oxacillin  M IC  of M R SA  19449 by  tw o- to four-fold. N one of com pounds tested here had 
any influence on the oxacillin MIC in the reference M SSA strain ATCC 25923.
Table 4. Ability of compounds (10 and 15) to decrease oxacillin MIC in S. aureus strains.
1 S. aureus ATCC 25923 1 MRSA 19449
Cpd Conc. 2 MIC Conc. 2 MIC
of cpd Reduction 3 A of cpd Reduction 3 A
[mM] [pg/mL] [mM] [pg/mL]
10 0.0625 No effect 1 0.125 From 256 to 64/32 4-8
15 0.03125 No effect 1 0.125 From 256 to 128/64 2-4
Abbreviations: Cpd, compound; Conc., concentration; A, activity gain. 1 Assays performed in 3-4 repetitions in 
either, the susceptible (ATCC 25923) or the resistant (MRSA 19449) strains. 2 Reduction from MIC of oxacillin 
tested alone to MIC of oxacillin in combination with 10 and 15, respectively (top /bottom MIC values noted in 
3-4 repetitions). 3 Activity gain assessed as the ratio of MIC of oxacillin to MIC of oxacillin in combination with 
10 and 15, respectively (see Equation (1), Section 3.3.1.), the range of A observed due to the MIC differences (top 
and bottom values) in 3-4 repetitions; A>4 for active compounds potentiating effects of antibiotics. Detailed 
results for all compounds tested are presented in Supplementary material (pp. 10-11).
2.3.3. Extended Biological Screening in S. aureus 
A ntibacterial A ctivity in A dditional Strains of S. aureus
C om pounds 14 -16  w ere tested further for their ad juvant-like effect w ith  a set of ten 
additional S. aureus isolates. Firstly, M IC  values of the m olecules w ere evaluated in  tw o 
clinical M SSA isolates (MM -O058, M M -N 072), seven M RSA (USA300 LAC, 5328, LG-N017, 
M M -O 021, R 45-C C 45, R 46-C C 22, CO L) and one V ISA  strain (M u50). D etailed results 
are presented in the Supplem entary section (Table S3). In line w ith  our observations 
described above, none of the 5-arylideneim idazolones 14-16  displayed any considerable 
antistaphylococcal activity against this set of S. aureus strains (MIC from 0.125 to >  1 mM).
A bility to Enhance A ntibiotic A ctivity
The ad juvant properties of com pounds 14 -16  in S. aureus clin ical isolates w ere next 
tested in com bination w ith oxacillin and the penicillinase-susceptible ß-lactam  antibiotic, 
am picillin. The second ß-lactam  antibiotic w as chosen based on its vulnerability  to enzy­
m atic hydrolysis, another im portant resistance m echanism  in S. aureus  against penicillin . 
Therefore, the results of the M IC reduction assay obtained on the activity of arylideneim - 
idazolones com bined w ith  oxacillin  and am picillin , respectively, m ight provide further 
insights into the possible m echanism  of action of the com pounds. C om plete results are 
presented in Supplem entary (Tables S4 and S5), w hile condensed in Figure 6, in  the case 
of desired activity  noted. The results obtained in  this set of experim ents indicated that 
each of the com pounds tested at the concentration of 0.0625-0.125 mM  had the capacity to 
reduce significantly the resistance to oxacillin  of som e bu t not each of the M RSA  strains 
tested (Figure 6a, Supplem entary Tables S4 and S5). O ne possible explanation for the lack 
of ad juvant activity of com pounds in som e of the strains selected for this study m ight be 
that these strains express PBP2a only w hen induced by the antibiotic, w hile others, for 





□  MM-O021 (MRSA MDR)
□  R45-CC45 (MRSA)
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Figure 6. The gain of activity (A) for ß-lactam antibiotics caused by active 5-arylideneimidazolone derivatives (14—16) 
in various clinical isolates of S. aureus. Antibiotics and clinical isolates of S. aureus, used: (a) oxacillin (OXA) in strains: 
MM-O021, Mu50, R46-CC22 and R45-CC45, respectively; (b) ampicillin (AMP) in the strains: MM-O021 and R45-CC45. 
Assays performed in 3-4 repetitions; A, calucated according to Equation (1) (Section 3.3.1), shown as arithmetic mean in 
case of different values obtained in the repetitions; A >  4 for active; compounds potentiating effects of antibioticu Detpiled 
resu(t4 for all strains explored are presented in Supplementary material (pp. 11-15).
Compounds 14-16  were able to decrease MIC values of oxacillin by four- to eight-fold 
in M R SA  isolates M M -O 021, R R45-C C 45, and R R46-C C 22, and the; V ISA  isolate M u50 
(Figure 6a). Notably, comppund 15 w as also able to deerease the MIC! values for ampicillin 
in the M RSA  strains M M -O 021 and R 45-C C 45 (Figure 6b ), w ith  A -values 10.7 and 6, 
respectively, w hile the am picillin  M ICs of the other tested strains w ere not m arkedly 
affected by com pounds 14-16  (Supplem entary Tables S6-S9). Similarly, these com pounds 
neither influenced the activity of oxacillin in M SSA strains M M -O 058 and M M -N 072, nor 
altered the oxacillin M ICs of M RSA strains U SA 300 LAC, 5328, LG-N 017, and COL.
To evaluate w hether com pounds 14-16  m ight affect the M ICs of the set of strains 
investigated for other antibiotic classes, w e next tested the chem osensitizing properties of 
com pounds 14-16  in com bination w ith the glycopeptide vancom ycin, the fluoroquinolone 
ciprofloxacin, and the m acrolide erythrom ycin. N one of derivatives altered the M ICs for 
vancom ycin, ciprofloxacin, and erythrom ycin in these strains of S. aureus (Supplem entary 
Tables S10-S14), suggesting that the com pounds interact specifically w ith PBP2a in some 
but not each strain of M RSA.
2.3.4. M olecular M odelling of the Interactions w ith PBP2a
In order to test w hether the activities of the com pounds on the oxacillin  M ICs of 
M RSA are related to their interactions w ith PBP2a, we next performed a series of m olecular 
m odelling studies. The docking results of selected com pounds to the PBP2a active site are 
presented in Figure 7, w hereas docking to the allosteric site of PBP2a is show n in Figure 8 
(com plete data are available in the Supplem entary Figures S1 and S2).
Figure 7. Docking results of selected compounds to the active site of PBP2a with indication of 
hydrogen bonds (a) green: 10, orange: 15; (b) green: 10, magenta: 16, (c) green: 10, cyan: 7, (d) green: 
10, yellow : 9.
Figure 8. Docking results of selected compounds to ths rllosteric site of PBP2a with indication of 
hydrogen bonds; (a) green: 10, orange: 15, (b) green: 10, magenta: 9, (c) green: 10, yellow: 20.
These m odelling studies show that the docking poser of com pounds to the active site 
are ve ry sim ilar ( Figure 7 ), and there is no obvious difference betw een the orieneation of 
compounds reducing the antibiotic MIC of oxacillin and com pounds w ithout this property.
Interestingly, w hen the com pounds w ere m odelled w ith  the allosteric site; of PBP2a, 
clear variations in orientations w ere noticed (Figure 8), although no consistent pose could 
be defined w hich m ay allow  to discrim inate betw een active and inactive com pounds.
To facilitate the interpretation of the results, ligand-protein interaction m atrices were 
prepared (Figure 9), w hich  captured the various interactions occurring in ligand-PBP2a 
com plexes as defined in docking.
Figure 9. Ligand-protein interaction matiix dlejticting contacts in (a) the active site of PBP2a, (b) the allosteric site of PBP2a; 
compounds for which antibiotic adjuvant properties have been indicated in our investigations are shaded.
This interacti on matriices highlliightt diffferences in the set of interactions form ed by 
particular structures, both at the active (Figure 9a) and allosteric sites (Figure 9b ) of PBP2a. 
C om pounds w ith  antibiotic ad juvant properties (Figure 7) share sim ilar positions of the 
com pound core in the PBP2a active site, although they adopt different orientations of the 
aromatic m oieties, w ith varying distances and angles towards Glu602. The position of the 
m ost active com pound 10 is in  the m iddle betw een the less active 15 depicted in  orange 
(Figure 7a) and 16 depicted in m agenta (Figure 7b). Both 10 and 15 form  hydrogen bond 
w ith S462, w hereas 16 interacted via hydrogen bond w ith N464. Com pound 7 (Figure 7c), 
w hich is characterized by a different chem ical structure also adopt different orientation in 
the active site of PBP2a. 11 is also in dicated by the set oe hydrogen bon ds formed (with S403, 
K430). Com pound 9 adopt sim ilar docking pose in the PBP2a active site to 16 (Figures 7d 
and 7b , respectively); how ever, w hen docking to the PBP2a allosteric site is considered, 9 
is the only com pound w hich  m akes contact w ith  G ln200 and the only one n ot in contact 
w ith  any of the am ino acids from  the set Lys148, Ser149, G lu150, and Arg151 (Figure 8b , 
Figure 9 ). Further analysis of docking outcom e to the allosteric site of PBP2a revealed that 
the m ost active com pound 10 orients its arom atic ring perpendicular in  com parison to 
other active com pounds (e.g., 15,  F igure 8a), and as the only com pound has contact w ith 
Lys148. C om pound 10 is also the only com pound w hich  does not in teract w ith  Tyr373 
(Figure 9 ). The m ajority  of com pounds also form  hydrogen bond w ith  M 372 and T216, 
w hereas 20 is bonded via this type of contact to E239, and G374.
As docking captures only one m om ent of ligand-protein contact, m olecular dynamic 
sim ulations were performed to provide a more detailed picture of the possible m echanism 
of action of active com pounds w ith  PBP2a. Figure 10 presents results for the m ost active 
com pound 10, w hereas results for com pounds 14- 16 are presented in the Supporting 
Inform ation (Supplem entary Figures S3 and S4).
Figure 10. Ligand-protein interaction diagrams obtained by molecular dynamic simulations for the most active compound 
10 for (a) the active site1; (b) the allosteric site of PBP2a.
M olecular dynam ic sim ulations show  that the stability of different poses of com ­
pounds in the allosteric site is m uch higher than in the active site of PBP2a, as the com ­
pound m oves from its initial position and doer not adopt any stable position in the active 
site. This suggests that the com pounds studied m ost probably act as allosteric ag en ti, 
w hich m ay im prove the ligand-probein contacts in the active site.
2.4. Biological Screening in the Gram -Negative Bacterial Species K. aerogenes
2.4.1. C hem osensitizer A ctivity in K. aerogenes
The influence of 5-arylideneim idazolones (7 -1 5 ,1 7 -1 9 ,2 1 )  and 5-arylidenethiazolones 
(22,23) was also tested w ith K. aerogenes strain Ea-289, w hich overexprecses the AcrAB-TolC 
efflux pum p and exhibits a porin-deficient phenotype [33]. A t first, M IC  values of com ­
pounds w ere determ ined (Table S1.5, Supplrm entary). Next, their abilities to reduce M ICs 
of the AcrAB-TolC subrtrates doxycycline (a tstracycline-class antibiotic) and erythrom ycin 
w ere studied (Table S16, Supplem entary). "These studies indicated that the addition of bhe 
arylidene compounds cfld neither affect fhe viability of strain Ea-289, nor caused significant 
reductions in the M IC values associated w ith doxycycline and erythrom ycin.
A subset of com pounds, nam ely 7 ,1 2 -1 6 ,1 9 , 20, w as also exam ined for the potential 
to increase the effectiveness of the antibiotics chloram phenicol, erythrom ycin, doxycycline, 
and the fluoroquinolone antibiotic norfloxacin, w hich all are substrates for AcrAB-TolC in 
K. aerogenes [34,35]. In addition to strain Ea-289, the adjuvant-like effect of the com pounds 
w as investigated in strain CM -64, w hich also overexpresses the AcrAB-TolC efflux pum p, 
although it has no changes in  porin content [36], and in  the Ea-289 derivatives, i.e., Ea- 
294 and Ea-308, w hich  are devoid of A crA B (Table S17, Supplem entary). Sim ilar to the 
situation in strain E a-289, none of the com pounds displayed a clear antibacterial activity 
against the set of K. aerogenes strains (Table 5 ), although com pounds 1 5 ,1 6 , and 19 w ere 
m ore effective ( >  4-fold) in strains Ea-294 and Ea-298 w hen com pared to the parental 
strain Ea-289, suggesting that 19 m ight interact w ith  AcrAB-TolC. In  contrast, the lack of 
an apparent difference in  M ICs betw een the AcrAB-TolC over-producing Ea-289 and the 
parental strain observed for compounds 7, 12, 13, 14, and 20 suggests that these compounds 
do n ot interact w ith  this m ultidrug efflux pum p, although such an interaction cannot be 
excluded since the real M IC  values for these com pounds in Ea-289 are m uch higher than 
2 m M , the highest concentration for com pounds tested in our assays.
Table 5. Antibacterial activity, represented by MIC values, of compounds 7, 12-16, 19, 20 against 
K. aerogenes strains (Ea-294, Ea-308, Ea-289, and CM-64).
Compound
Minimal Inhibitory Concentration (MIC) [mM]
Ea-294, Ea-308 ** Ea-289 ** CM-64 **
7 * 2 > 2 > 2
1 2 * 1 > 2 > 2
13 2 > 2 > 2
14 2 > 2 > 2
15* 0.125 > 2 > 2
16 0.5 > 2 > 2
19 * 0.25 > 2 > 2
20 * 2 > 2 > 2
* Compounds precipitated after addition of MH II. ** K. aerogenes strains; Ea-294, Ea-308—devoid of AcrAB; 
Ea-289, CM-64—with overexpression of AcrAB-TolC with or without change in porin content, respectively.
Additionally, none of the com pounds 7 ,1 2 -1 6 ,1 9 , or 20 w ere able to reduce M ICs of 
the antibiotics (A <  2), w hen added at concentrations corresponding to 1 /4  of their M IC, 
w hich  is in  line w ith  earlier findings for 5-arylideneim idazolones and K. aerogenes [27]. 
The results for com pounds 16 and 20 obtained in the MIC reduction assay w ere described 
previously [27] or are presented in the Supplem entary section (Supplem entary Table S17).
2.4.2. Real-Tim e Efflux A ssay
C om pounds 7 ,1 2 -1 6 ,1 9 , and 20 w ere also assessed for their EPI property in K. aero­
genes strain Ea-289 w ith the use of a real-time efflux (RTE) assay. Results for compounds 16 
and 20 w ere previously  described [27]. The experim ent is based on the m easurem ent of 
the extrusion of a fluorescent dye from  bacterial cells overproducing efflux pum p trans­
porters in the presence and absence of com pounds tested. The dye used in  this assay, 
1,2' -d inap hthylam ine (1,2 '-dN A ), is a substrate for the AcrAB-TolC efflux pum p, and is 
strongly fluorescent upon incorporation into a phospholipid bilayer, although it is alm ost 
non-fluorescent in an aqueous solution [37,38].
The data obtained w ithin this assay indicated that the addition of the 5-arylideneim ida- 
zolones led to a decrease in the fluorescence intensity  o f 1 ,2 '-d N A  in bacterial cells 
treated w ith  these com pounds. A s our previous study already indicated an  increased 
fluorescence qu enching due to m olecular interactions betw een the fluorophore and 5- 
arylideneimidazolones [27], we quantitatively compared the effectiveness of 5-arylideneim i- 
dazolones in the inhibition of the extrusion of 1 ,2 '-d N A  by calcu lating the inhibition ef­
ficiency (IE ) of each com pound. This com parison show ed that the com pounds tested 
w ere able to inhibit the extrusion of the fluorescent dye ou t of K . aerogenes Ea-289 cells 
(Figure 11). The h ighest EPI activity  w as observed for com pound 19, w hich blocked the 
export of 1,2'-dN A  in Ea-289 by 90 %. A likew ise strong blocking efficacy (IE =  83 %) w as 
also noticed for compound 12, w hile the low est inhibitory effect w as found for compound 
13 (IE =  23 %).
7 12 13 14 15 16 19 20
Compound
Figure 11. Inhibition efficiency (IE) of imidazolone derivatives 7,12-16,19, and 20 towards extrusion 
of 1,2'-dNA in K  aerogenes strain Ea-289) over-producing AcrAB-TolC. IE calculated according to 
Equation (2) (Section 3.3.2.). IE=100% i- a tested compound totally inhibits the dye-substrate efflux.
2.5. Drug-Likeness Study
2.5.1. W ater Solubility
Six representatives of 5-arylideneim idazolones (9-12 , 15, 19) w ere chosen for the 
determ ination of w ater solubility. U V  spectroscopy w as used for the estim ation of con­
centrations of com pounds according to the m ethod described earlier [39,40]. A cquired 
U V  at) sorbance, calculated m eans, and standard deviations for tested com pounds are 
presented in Supplem entary "Table S18. Solubility  results, presented in Table 6, point out 
that com pounds from the sam e group) (A or B, Tables 1 and 2) w ith the tw o-ring aromatic 
m oiety are m ore soluble than com pounds w ith the fluorene m otive (Group A: 9 ,1 0 ,1 1  vs. 
n2; Group B: 15 vs. 19). M oreover, com paring compoundh w ith the same arylidene m oiety 
(t1-2 vs. 19) and various positions of am ine m otives, such as am ine at position 2 or 2 and 3, 
respectively, show  -hat the presence of a m orpholine m oiety connected by a propyl linker 
at position 3 (19) im proves the w atar volubility (from  1.645 to 199.467 m M lL ). "The m ost 
soluble of tested -om p onnd s w as com pound 15t w hich  could b r  d iscolved in  w ater a t a 
concentration of up to 205.502 m M /L .
Table 6. Water solubility, presented in m g/m L and m M /L, of compounds 9-12,15,19.







2.5.2. Stability in D ifferent pH Conditions
C om pounds 9 -12 , 15, and 19 w ere also tested for their stability in  acidic and basic 
conditions. This assay w as carried out for 48 h and samples were taken at six-time intervals 
(10 min, 1 h, 2 h, 3 h, 24 h, 48 h). Stability of the compounds was determined using the TLC 
m ethod. These studies confirm ed that 5-arylideneim idazolones are usually more stable in 
acidic conditions, w ith  four out of six com pounds (1 0 -1 2 ,1 9 ) being stable for at least 2 h, 
and com pounds 10-12  being stable for 24 h. In basic conditions, only com pounds 10 and 
15 w ere stable for 24 h. C om pound 10 w as the m ost stable one, g iving one degradation 
product w hich was observed, in both conditions, after 48 h. Results with details, including
time of degradation of products obtained, are presented in the Supplem entary (Tables S19 
and S20).
2.5.3. D rug-D rug Interactions (DDI)
C onsidering that the com pounds are designed to be used clin ically  in com bination 
w ith  antibiotics, inform ation about potential D D I is crucial. For this reason, m etabolic 
in silico and in vitro assays w ere perform ed. In  com puter-aided studies, the M etaSite 
program w as used to predict potential products of CYP3A4 metabolism for the entire series 
due to a significant involvem ent of this isoform of cytochrome P450 in drug metabolism. In 
case of in vitro assays, establishm ent of IC50 of CYP3A4 w as performed for the m ost active 
com pounds 15 and 19 selected on the basis of the biological screening.
In Silico Assays
Possible m etabolic paths and sites of m etabolic biotransform ation  w ere predicted 
using the M etaSite 6.0.1 com puter program  provided by M olecular D iscovery Ltd. The 
probable sites of m etabolism  w ere obtained w ith an application of com putational m odels 
of liver, skin, brain  and cytochrom es. In the m ajority  m odels, the m ost probable site of 
m etabolism  for the com pounds tested are positions 3  and 5  in the m orpholine ring. In 
the case of CYP3A 4 m etabolism , the m ost likely places of m odification dependent on the 
position of am ine, i.e., only  positions 3  and 5  in m orpholine ring w ere m ore than 60%  
probable for the am ine at position 2 (7 -13 , 22, 23), w hereas the alkyl group connected 
directly to m orpholine w as also significantly probable for com pounds w ith the aminealkyl 
fragm ent at position 3 (14-21). The m ost probable m echanism  in CYP3A4 m etabolism  was 
O -dealkylation. Additionally, N -dealkylation (14-21, 23), dehydrogenation (7 and 14) and 
aliphatic carbonylation (14-21) w ere the highly probable (>60% ) m echanism s. Results for 
com pounds 15 and 19, selected for in vitro assays, are presented in the Supplem entary 
(Figures S5 and S6, respectively).
DDI In Vitro Assays
The m ost active chem osensitizers found, either for G ram -positive (15) or G ram ­
negative (19) strains, w ere tested for their D D I-risk using the lum inescent CYP3A 4 P450- 
Glo™  assay. Ketoconazole served as a reference inhibitor of CYP3A4. Although predicted 
in silico as show ing a high probability of m orpholine ring interaction w ith C YP3A 4, com ­
pounds 15 and 19 did not influence CYP3A 4 in vitro in concentrations low er than 25 gM  
(Figure 12). Even at the highest concentration tested, 25 gM , com pound 15 did not reach 
50%o of inhibition of C YP3A 4 (Figure 12a ). Sim ilarly, com pound 19 w as a w eak C YP3A 4 
inhibitor w ith IC 50 =  24.9 gM  (Figure 12b ).
(a) (b)
Figure 12. Inhibition of CYP34A activity by compounds 15 (a) and 19 (lb) and reference ketoconazole experssed with 
IC50 values.
Results obtained in  this study indicated favorable "d ru g -lik e" properties for the 
com pounds tested, notably a low  risk of potential D DI. C om pound 15, in particular, did
not affect CYP3A4 w ithin the concentration range tested.
2.6. Structure A ctivity Relationships
5-A rylideneim idazolones (7-21) and 5-arylidenethiazolones (22, 23) possess an am - 
phiphilic structure. They include a bu lky arom atic m oiety  at position 5  and an am ine 
fragm ent at position 2 (group A  and C, Tables 1 and 2 ) or at position 2 and 3 (group B, 
Table 2),  containing a differently linked morpholine. This variety of topology, together with 
biological screening results, enables a comprehensive analysis of possible structure-activity 
relationships (SAR).
C om pounds (7-23) w ere tested for their ability  to restore oxacillin  activity  in  M RSA  
19449, and two of them (10 and 15) showed significant (4 -  8-fold) reduction of the antibiotic 
MIC (Table 4). Additionally, the assays performed in ten S. aureus strains (2 M SSA, 7 M RSA 
and 1 VISA) for com pounds 14-16  displayed that these com pounds w ere able to decrease 
oxacillin MIC up to 8-fold (Figure 6a). Notably, the active oxacillin "ad juvants" (1 0 ,14 -16 ) 
therefore have been identified am ong im idazolones, and three of them  represent Dim roth- 
rearranged topology (14-16). It is w orth  to underline that the arylidene m oiety  of the 
active com pounds is lim ited to only  non-condensed rings, i.e., the phenoxyphenyl (10, 
16) or b iphenyl (14, 15) m oieties. This is in contrast to previous studies, w hich  have 
indicated the fused rings as distinctly more profitable in the case of im idazolones w ith the 
corresponding am ine topology (position 3) [27,41]. In accordance w ith the present results, 
the preceding studies have also show n that am ine at position 2 and 3, corresponding to 
group B, is more profitable, although different am ines have been under consideration [27]. 
This suggests a predom inant role for the substitution topology of the com pounds obtained 
by D im roth rearrangem ent. For instance, m orpholine looks as it is a good bioisoster of the 
m ethylpiperazine presented in the previously found oxacillin "ad ju van ts" [27]. A deeper 
insight into structural features of the active com pounds (10 and 14-16) dem onstrates the 
aromatic biphenyl m oiety as the most favorable (15 vs. 16). Furthermore, the linker between 
the m orpholine and the im idazolone has some im pact, i.e., the longer (C3) linker could be 
superior compared to the shorter (C2) one (15 vs. 14, Table 4 , Supplem entary Table S2 and 
Figure S6). The assays w ith ampicillin in the same strains, performed for compounds 14-16, 
reinforce this conclusion. H ence, the biphenyl-derived C3-linked im idazolone com pound 
15 was outstanding among these three, causing significant reduction of the am picillin M IC 
in two M RSA strains (Figure 6b ).
The longer linker (C3) is associated w ith  better flexibility and this could explain  the 
different orientations of the aromatic m oieties of the com pounds adopting to the allosteric 
site of PBP2a. Follow ing the exam ple of the linker of the group B, this should also apply 
to chem ical functions less rigid than ones of groups A  and C, although this conclusion 
requires further studies based on a larger population of com pounds.
Sum m ing up, results obtained in  various M RSA  strains point out the beneficial role 
of (1) non-fused arom atic rings, i.e., b iphenyl and phenoxyphenyl ones, (2) D im roth- 
rearranged topology of substituents at the im idazolone core (group B) and (3) C 3-linker 
for the cyclic am ine at position 3 of the im idazolone, for the desirable ad juvant activity. 
Taking into consideration the other m odifications perform ed, it looks as if the substitution 
w ith  a m orpholine-containing am ine at position 2 (group A) w as less effective, w hile the 
replacem ent of the im idazolone w ith the thiazolone (group C) failed.
Furtherm ore, com pounds 7-23  w ere tested for their chem osensitizer activity  in the 
M D R  strain of K. aerogenes. N one of these com pounds show ed significant reduction of 
either doxycycline or erythrom ycin M IC. N evertheless, RTE assays indicated  that these 
com pounds w ere able to block the dye-substrate efflux by  AcrAB-TolC pum p, including 
six m em bers (7 ,1 2 ,1 4 -1 6 ,1 9 )  causing potent inhibitory  action (IE >50  %). Two the m ost 
active compounds, namely 12 and 19, contain the triple fused ring of fluorene. Interestingly, 
another triple-fused ring moiety, i.e., anthracene, provided significantly lower EPI potency
com pared to com pounds w ith  the sam e am ines and sim ilar substituent topology (19 vs. 
20 and 12 vs. 13, Figure 11) . In general, the role of the arom atic substituent at position 
5 should be crucial for the EPI properties to give the follow ing order: fluorene (1 9 ,1 2 ) > 
phenylbenzene (15, 7 ,1 4 ) >  phenoxybenzene (16) >  anthracene (20 ,13). A n im pact of the 
substituent topology has also been  noted, indicating the beneficial role for the D im roth- 
rearranged topology of group B  in com parison to the 2-extended topology of group A  (19 
vs. 1 2 ,1 5  vs. 7 and 20 vs. 13, Figure 11). In the case of com pounds w ith  different lengths 
of linker (C3 vs. C 2), the longer linker provided a distinctly  m ore potent A crA B-TolC 
inhibitory action, as noticed in 15 vs. 14, Figure 11 . Thus, the last two SA R conclusions for 
K. aerogenes are in  good agreem ent w ith  those from  the studies w ith  S. aureus. A lthough 
the fluorene derivatives 1 2 ,19 , the m ost active AcrAB-TolC EPI in this study, did not act as 
oxacillin  ad juvants in S. aureus, a sim ilar EPI activity  w as found for the active adjuvants 
14-16. The biphenyl compound (15), which was identified as the m ost active in the various 
S . aureus  assays, especially, provides an interesting exam ple in the search of an antibiotic 
adjuvant with a w ide range of actions, including M DR m echanism s of both Gram -positive 
and G ram -negative bacteria.
Results for com pounds 9 -1 2 ,1 5 ,1 9 , investigated on  their drug-like properties, indi­
cated that the m ost prom ising p -phenylbenzylidene derivative 15, dem onstrated also the 
m ost favorable w ater solubility (205.502 m M /L ) am ong the com pounds studied. In the 
chemical stability assay conducted at various pH values, the best stability was obtained for 
the 4-phenoxybenzylidene com pound (10), w hile com pound 15 stood out in this series as 
m ore stable under alkaline condition than under acidic ones.
The assays in vitro on CYP3A 4 inhibitory properties for the m ost active com pounds 
from the studies w ith S. aureus (15) and K. aerogenes (19) indicated that the fluorene analogue 
(19) had slightly less favorable properties than those of 15, show ing a w eak C YP3A 4 
inhibition (IC50 =24.9 gM, Figure 12b). Hence, the p-phenylbenzylidene derivative 15 gives 
a good prospect to be com bined w ith antibiotics w hich are m etabolized through CYP3A4, 
due to rather negligible risk of effects on the m etabolism  of these drugs.
3. M aterials and M ethods
3.1. Chemical Synthesis
R eagents w ere purchased from  Sigm a A ldrich  (D arm stadt, G erm any), A lfa A esar 
(Karlsruhe, G erm any) or Acros O rganics (Geel, Belgium ). The progress o f the reactions 
w as m onitored by  thin  layer chrom atography (TLC). It w as carried out on  silica gel 60 
F254 plates (0.2 mm M erck, Darmstadt, Germany). UV light w as used for the visualization 
of spots. A  M EL-TEM P II apparatus (LD  Inc., Long Beach, C A , U SA ) w as em ployed to 
determ ine m elting points (m .p.) and these m p are uncorrected. The 1H -N M R  and 13C- 
N M R  spectra w ere obtained on a M ercury-V X 300 M z spectrom eter (Varian, Palo Alto, 
C A , U SA ) in D M SO -d6. In 1H -N M R  spectra, chem ical shifts w ere reported in  parts per 
m illion (ppm ) on the 6 scale. The solvent signal served as an internal standard. D ata are 
reported as follows: Chemical shift, m ultiplicity (s, singlet; br.s, broad singlet; d, doublet; d 
def, doublet deformed; m, multiplet), num ber of protons, position of protons (Ar- aromatic 
m oiety at position 5, Pp— piperidine, M or— morpholine). M ass spectra were recorded— on 
a U P L C -M S/M S system  consisting of a W aters ACQUITY®UPLC® (W aters C orporation, 
M ilford, M A , U SA ), w hich  is coupled to a W aters TQ D  m ass spectrom eter (electrospray 
ionization mode ESI-tandem  quadrupole). Chrom atographic separations w ere carried out 
using the A cquity  U PLC  BEH  (bridged ethyl hybrid) C 18 colum n; 2.1 x  100 m m 2, and 
1.7 gm particle size, equipped w ith Acquity UPLC BEH C18 VanGuard precolumn (Waters 
C orporation, M ilford, M A, USA); 2.1 x  5 m m 2, and 1.7 gm particle size. The colum n w as 
maintained at 40 °C and eluted under gradient conditions from 95% to 0% of eluent A over 
10 m in at a flow  rate o f 0.3 m L m in - 1 . E lu ent A: w a te r/fo rm ic  acid (0.1% , v /v ); eluent 
B: aceto n itrile /form ic acid (0.1% , v /v ). C hrom atogram s w ere obtained using W aters eA 
PDA detector. Spectra w ere analyzed in the 200-700 nm range w ith 1.2 nm resolution and 
sampling rate 20 poin ts/s. The M S detection settings of the Waters TQD m ass spectrometer
w ere as follow s: source tem perature 150 °C, desolvation tem perature 350 °C  desolvation 
gas flow rate 600 L-h- 1 , cone gas flow 100 L-h- 1 , capillary potential 3.00 kV, cone potential 
40 V. Nitrogen w as used for both nebulizing and as drying gas. Data was collected in a scan 
m ode ranging from  50 to 1000 m /z  in tim e 0.5 s intervals. D ata acquisition softw are w as 
M assLynx V  4.1 (W aters C orporation, M ilford, M A, U SA ). R etention tim es (tR) are given 
in m in. The U P L C /M S  purity of com pounds 7-23  w as determ ined (%). The synthesis of 
interm ediates 24-30 , 32 -38  and products 7 -1 0 ,1 2 -1 7 ,1 9 -2 1  w as described earlier [27,28].
3.1.1. G eneral Procedure to O btain 5-A rylidenethioxothiazolidin-4-one (31)
To flat-bottom  flask 2-thioxothiazolidin-4-one (3.33 g, 25 m m ol), acetic acid (25 m L), 
sodium  acetate (8.33 g, 100 m m ol) and appropriate aldehyde (25 m m ol) w ere added. The 
reaction mixture w as refluxed for 5 h. Then, it was stirred at room temperature for 20 h. The 
progress of the reaction was monitored by TLC (chloroform: ethyl acetate/1:1). Purification 
w as perform ed using crystallization from acetic acid.
(Z )-5-((9H -Fluoren-2-yl)M ethylene)-2-Thioxothiazolidin-4-one (31)
9H-Fluorene-2-carbaldehyde (25 mmol, 4.86 g) and 2-thioxothiazolidin-4-one (25 mmol,
3.33 g) w ere used. Yellow  solid. Yield 63.73% ; m p 259-261  °C. C i7H n N O S 2 M W  309.41. 
L C /M S ± : (ESI) m /z  [M + H]+ 310.16. 1H -N M R  (D M SO -d6, ppm ): 6 13.79 (s, 1H, N 3-H ),
8 .05-8 .00  (d def., 1H, A r-5-H ), 7 .97-7 .92  (d def., 1H, A r-4-H ), 7.75 (s, 1H, A r-1-H ), 7.67 (s, 
1H, C =CH ), 7 .62-7.57 (m, 2H, Ar-3,8-H), 7.41-7.33 (m, 2H, Ar-6,7-H), 3.98 (s, 2H, Ar-9-CH2).
3.1.2. G eneral Procedure to O btain 5-A rylidene-2-M ethylthio-Thioxothiazol-4-one (39)
Sodium  (0.506 g, 22 m m ol) w as added to ethanol (34.10 m L). To this solution, the 
appropriate 5-arylidenethioxothiazolid in-4-one (22 m m ol) w as added and the reaction 
m ixture w as stirred at room  tem perature for 3 min. Then, iodom ethane (3.34 g, 22 m m ol) 
w as added and the reaction m ixture w as stirred for 24 h. The progress of the reaction 
w as m onitored by  TLC  (chloroform : ethyl ace ta te/1 :1 ). Product w as purified by acetone 
crystallization.
(Z )-5-((9H -Fluoren-2-yl)M ethylene)-2-(M ethylthio)Thiazol-4(5H )-one (39)
(Z )-5-((9H -Fluoren-2-yl)m ethylene)-2-thioxothiazolidin-4-one (31) (22 m m ol, 6.80 g) 
and iodom ethane (22 m m ol, 3.34 g) w ere used. Yellow solid. Yield 99.0 %; mp 202-204 °C. 
C 18H 13N OS2 M W  323.43. L C /M S ± : (ESI) m/z [M + H]+ 324.18. 1H-NM R (DM SO-d6, ppm): 
6 8 .08-8.00 (d def., 1H, Ar-5-H), 7.99-7.93 (d def., 1H, Ar-4-H), 7.89 (s, 1H, C =CH ), 7.86-7.78 
(m, 1H, Ar-1-H), 7.71-7.65 (d def., 1H, Ar-3-H), 7 .63-7.57 (d def., 1H, Ar-8-H), 7.43-7.31 (m, 
2H, Ar-6,7-H ), 3.98 (s, 2H, A r-9-CH 2), 2.81 (s, 3H, S-CH 3).
3.1.3. Synthesis of Final Products (11 ,18 , 22, 23) -  G eneral Procedure
(Z )-5-Arylidene-2-(methylthio)-3H -imidazol-4(5H )-one or (Z )-5-arylidene-2-(methylthio) 
thiazol-4(5H )-one (3 -5  m m ol) w ith proper am ine (3 -6  m m ol) w as heated and stirred w ith 
controlled temperature (120-130 ° C) for 15 min. After that time, ethanol (15 mL) w as added. 
R eaction m ixture w as refluxed for 5 -6  h and then stirred a t room  tem perature for 20 h. 
Then, gaseous hydrochloride acid w as used for conversion into hydrochloride form s. If 
necessary, crystallization using ethanol w as perform ed.
(Z)-5-(N aphthalen-1-ylm ethylene)-2-(4-M orpholinopiperidin-1-yl)-Im idazol-4(5H )-one 
H ydrochloride (11)
(Z )-5-(N aphthalen-1-ylm ethylene)-2-(m ethylthio)-im idazol-4(5H )-one (38) (5 m m ol,
1.34 g) and 4-m orpholinopiperidine (5 mmol, 0.85 g) were used. Yellow solid. Yield 39.26%; 
mp 244-249 °C. C23H26N4O2-3HCl-0.5H2O M W  508.87. L C /M S ± : purity 96.92% tR =  3.66, 
(ESI) m /z  [M + H]+ 391.24. 1H -N M R  (D M SO -d6, ppm ): 6 11.88 (s, 1H, N H +), 8.20 (s, 1H, 
N3-H), 8 .11-8.05 (m, 1H, Ar-8-H), 7.98-7.90 (m, 2H, Ar-4,5-H ), 7.62-7.49 (m, 4H, Ar-2,3,6,7-
H), 7.25 (s, 1H, C H =C ), 4 .63-2 .90  (m, 13H, Mor, Pp-2,4,6-H ), 2 .31-2 .19 (m, 2H, Pp-3,5-H b), 
1 .89-1.75 (m, 2H, Pp-3,5-Ha).
(Z)-5-(N aphthalen-1-ylm ethylene)-2-A m ino-3-(3-M orpholinopropyl)-Im idazol-4(5H )- 
one H ydrochloride (18)
(Z)-5-(Naphthalen-1-ylmethylene)-2-(methylthio)-3H-imidazol-4(5H)-one (35) (5 mmol,
1.34 g) and 3-m orpholinopropan-1-am ine (6 m m ol, 0.87 g) w ere used. Yellow solid. Yield 
64.54 %; m p 265 -2 6 8  °C. C 21H 25C lN 4O 2 M W  400.90. L C /M S ± :  purity  99.69%  tR= 3.56, 
(ESI) m/z [M + H] 365.19. 1H -N M R (D M SO -d6, ppm ): 6 11.54 (br. s, 1H, N H +), 9.55 (s, 1H, 
N 3-H ), 8 .15-8 .04  (m, 1H, A r-8-H ), 8 .00-7 .91 (m, 2H , A r-4,5-H ), 7 .84-7 .72 (m, 1H, Ar-2-H ), 
7 .65-7 .53 (m , 3H , A r-3,6,7-H ) 7 .39-7 .27  (m, 1H, C H =C ), 4 .39 -2 .77  (m , 12H, N 3-C H 2-C H 2- 
CH 2, M or), 2 .11-1 .87 (m, 2H, N 3-CH 2-CH2). 13C-N M R (DM SO -d6, ppm): 6 133.79,133.48, 
1 3 1 .7 8 ,1 3 1 .6 1 ,1 2 9 .1 8 ,1 2 8 .9 5 ,1 2 6 .0 6 ,1 2 6 .0 1 ,1 2 5 .6 0 , 66.59, 53.77, 5 3 .7 2 ,4 0 .7 9 ,4 0 .5 0 ,4 0 .2 2 , 
39.94, 39.66, 39 .38,39.09.
(Z)-5-((9H -Fluoren-2-yl)m ethylene)-2-(4-M orpholinopiperidin-1-yl)Thiazol-4-one 
H ydrochloride (22)
(Z )-5-((9H -Fluoren-2-yl)m ethylene)-2-(m ethylthio)thiazol-4(5H )-one (39) (3 mmol, 0.97 
g) and 4-m orpholinopiperid ine (3 m m ol, 0.51 g) w ere used. Yellow solid. Yield 2.46 %; 
m p 244 -2 4 6  °C. C 26H 28C lN 3O 2S M W  482.04. L C /M S ± : purity  93.63%  tR = 5.13, (ESI) 
m /z  [M + H] 448.33. 1H -N M R  (D M SO -d6, ppm ): 6 8 .06-7 .98  (m , 1H, A r-5-H ), 7 .97-7 .92 
(m, 1H, A r-4-H ), 7.81 (s, 1H, C H =C ), 7.70 (s, 1H, A r-1-H ), 7 .67-7 .63  (d def., 1H, A r-3-H ), 
7 .61-7 .57 (d def., 1H, A r-8-H), 7 .42-7.32 (m, 2H, Ar-6,7-H ), 4 .03-3 .55 (m, 6H, Ar-9-H, Mor-
2,6-H ), 3.51-2.54 (m, 9H, M or-3,5-H , Pp-2,4,6-H ), 2.16 (br. s, 2H, Pp-3,5-H b), 1.67 (br. s, 2H, 
Pp-3,5-Ha).
(Z )-5-((9H -Fluoren-2-yl)m ethylene)-2-((3-M orpholinopropyl)am ino)Thiazol-4(5H )-one 
H ydrochloride (23)
(Z )-5-((9H -Fluoren-2-yl)m ethylene)-2-(m ethylthio)thiazol-4(5H )-one (39) (3 m m ol, 
0.97 g) and 3-m orpholinopropan-1-am ine (4 m m ol, 0.58 g) w ere used. Yellow solid. Yield 
13.44 %; m p 243 -2 4 5  °C. C 24H 26C lN 3O 2S M W  456.00. L C /M S ± : purity  91.98%  tR =  5.05, 
(ESI) m/z [M + H] 420.22. 1H-NM R (DM SO-d6, ppm): 6 8 .03-7.96 (m, 1H, Ar-5-H), 7.94-7.84 
(m, 1H, Ar-4-H), 7 .83-7.68 (m, 1H, Ar-3-H), 7.67-7.48 (m, 3H, Ar-1,8-H , C2-N H ), 7 .44-7.18 
(m, 3H , A r-6,7,8-H ), 4 .01 -3 .67  (m, 2H , A r-9-H ), 3 .67-2 .83  (m, 8H, M or), 2 .37 -2 .07  (m , 4H , 
N3-CH2-CH2-CH2), 1.80-1.62 (m, 2H, N 3-CH 2-CH2). 13C-NM R (DM SO-d6, ppm): 6 144.31,
1 4 4 .2 1 ,1 4 2 .8 0 ,1 4 0 .7 0 ,1 3 3 .1 5 ,1 2 9 .3 4 ,1 2 9 .1 5 ,1 2 8 .6 2 ,1 2 7 .4 2 ,1 2 6 .3 3 ,1 2 5 .7 1 ,1 2 1 .1 0 ,1 2 1 .0 6 , 
66.64, 55.92, 53 .75 ,40 .79 , 40.50, 40.22, 39.94, 39.66, 39 .38 ,39 .09 , 25.95.
3.2. Crystallographic Studies
Single crystals suitable for an X-ray structure analysis were obtained from the mixture 
of m ethanol and butan-2-ol by  slow  evaporation of the solvent at room tem perature.
Intensity  data w as collected u sing the XtaLA B Synergy-S diffractom eter, equipped 
w ith  the C u (1.54184 A) K a  radiation source and graphite m onochrom ator. The phase 
problem  w as solved by  application of d irect m ethods in SIR-214 [42] and non-hydrogen 
atoms w ere refined anisotropically using w eighted full-m atrix least-squares on F2. Refine­
m ent and further calculations were carried out in SH ELXL-2014 [43]. The hydrogen atoms 
bonded to carbon atom s w ere included in the structure a t idealized positions and w ere 
refined using a riding m odel w ith Uiso(H) fixed at 1.2 Ueq of C. Hydrogen atoms attached 
to nitrogen and oxygen atom s w ere found from  the difference Fourier m ap and refined 
w ithout any restraints. For m olecular graphics M ERCURY [44] program  w as applied.
7: C 20H 26C lO 5N 3, Mr =  423.89, crystal size =  0.05 x  0.08 x  0.56 m m 3, m onoclinic, 
space group P21/c ,  a =  16.5221(3) A, b =  6.9026(1) A, c =  18.1445(3) A, V  =  2011.85(6) 
A 3, Z =  4, T =  100(2) K, 37915 reflections collected, 3786 unique reflections (Rint =  0.0575), 
R1 =  0.0316, w R2 =  0.0898 [I >  2c(I)], R1 =  0.0325, w R2 =  0.0914 [all data].
CCDC 2039456 contains the supplem entary crystallographic data. These data can be 
obtained free of charge from The C am bridge Crystallographic D ata Centre via www.ccdc. 
cam .ac.u k/d ata_req u est/cif (accessed on 18 February 2021).
3.3. Biological Assays
The strains of S. aureus and K. aerogenes w ere cultured and then m aintained on 
C olum bia agar (bioM erieux, M arcy-l'E toile, France) or Trypticase Soy A gar II (TSA  II; 
Becton D ickinson, Franklin Lakes, NJ, U SA ) supplem ented w ith  5%  sheep blood, respec­
tively. C ation-ad justed  M ueller-H inton (M H  II) broth  necessary for the m icrobiological 
assays was purchased from bioM erieux (Lyon, France). Antibiotics needed in susceptibility 
testing: oxacillin , am picillin , vancom ycin, ciprofloxacin, ch loram phenicol, doxycycline, 
norfloxacin, and erythrom ycin (lactobionate) were obtained from Sigm a-Aldrich (St. Louis, 
M I, U SA ) or A m dipharm  (London, U nited K ingdom ). 5-arylideneim idazolone and 5- 
arylidenethiaziolone derivatives w ere dissolved in  D M SO  (M erck, Stuttgart, G erm any) 
to a concentration of 40  m M  and the solutions obtained w ere stored at -20 °C  until used. 
Furtherm ore, the follow ing chem ical com pounds w ere applied to perform  the RTE assay: 
K 2H PO 4 and M gC l2 (Sigm a-A ldrich, Saint Louis, M O , U SA ) to prepare potassium  phos­
phate buffer (PPB), CCCP (Sigm a-Aldrich, Saint Louis, M O, USA ), 1,2'-dN A  (TCI-Europe, 
Zw ijndrecht, Belgium ), glucose (Sigm a-Aldrich, Saint Louis, M O, USA).
3.3.1. Biological Screening in S. aureus C linical Isolates— Susceptibility Testing
D eterm ination of M IC  values, i.e., intrinsic antibacterial activity, of products and 
antibiotics (oxacillin , am picillin , vancom ycin , ciprofloxacin, and erythrom ycin) in  the 
presence and absence of com pounds tested w as conducted by the use of a standard 2-fold 
m icrodilution m ethod in cation-adjusted M ueller H inton broth follow ing the C linical and 
Laboratory Standards Institute (CLSI) guidelines [45]. The MIC values were detected using 
an Infinite M 200 pro Tecan m icroplate reader (Tecan® France, SA -Lyon, France). M IC 
determ inations w ere conducted in 96-w ell m icrotiter plates and repeated 3 -4  times.
Initially, M ICs of a series of im idazolone derivatives were assessed against susceptible 
(reference) and M D R  strains of staphylococci. N ext, M IC  values of the aforem entioned 
antibiotics w ere determ ined in the absence and presence of im idazolone derivatives to as­
sess the chemosensitizing effect of these compounds. The final concentrations of molecules 
used in the assays w ere n ot greater than the values of their respective M IC s/4  to ensure 
that inhibition did not result from  intrinsic antibacterial activity  of these com pounds. 5- 
arylideneim idazolones and 5-arylidenethiazolones, w hich  precipitated after addition to 
bacterial suspension in M H  II m edium , w ere tested at the highest concentrations at w hich 
precipitation w as not observed. The final concentration of d im ethyl sulfoxide (DM SO ) 
used to prepare solutions of com pounds tested never exceeded 2.5%  and did not influ­
ence bacterial viability. A ntibacterial activity  of com pounds and antibiotics am picillin , 
vancom ycin, ciprofloxacin, and erythrom ycin w as recorded as the lowest concentration of 
m olecules able to inhibit bacterial grow th after 18 h incubation a t 37 ° C. The incubation 
of bacterial strains exposed to oxacillin  paired w ith  com pounds tested w as conducted at 
35 °C  and extended to 24 h due to frequent occurrence of heterogeneity  am ong M RSA  
strains. The results are presented as activity gain (A) param eter w hich w as calculated as 
ratio of M IC of a certain antibiotic (M ICAnt) to its M ICAnt+Comp, observed in com bination 
w ith a tested com pound (7 ,1 2 -1 6 ,1 9 , or 20; Equation (1)) [25,40].
3.3.2. M olecular M odeling
Com pounds w ere docked to the crystal structure of PBP2a protein (PDB code: 3ZFZ) 
using G lide [21,46]. Three-dim ensional conform ations of com pounds w ere generated in
MICAnt
(1)
LigPrep and docking w as perform ed to the active and allosteric site of this protein : grid 
centering at S403 and S240, respectively [21,46,47].
To evaluate the m echanism  of action  of com pounds w ith  PBP2a, the com pounds 
w hich  w ere found to restore oxacillin  activity  in M RSA  19449 (10, 14-16) u nderw ent 
m olecular dynam ic sim ulations. The docking poses receiving the highest scores w ere 
used as starting poses for sim ulations, w hich w ere perform ed in D esm ond, using a TIP3P 
solvent m odel [48,49]. Each sim ulation lasted 100 ns.
3.3.3. Biological Screening in K. aerogenes— Susceptibility Testing
M IC values of 5-arylideneim idazolone derivatives w ere determ ined follow ing CLSI 
recom m endations as in the m ethods described for S. aureus (Section 3.3.1) [45].
3.3.4. Real-Tim e Efflux A ssay
The inhibitory activity  of 5-arylideneim idazolone derivatives tow ards A crA B-TolC 
mediated efflux of 1,2'-dN A w as detected in K. aerogenes strain Ea-289 by using a real-time 
fluorom etric m ethod. In a first step, bacterial cells w ere loaded w ith  the environm ent­
sensitive fluorescent m em brane probe, 1 ,2 '-dN A , in the presence o f the EPI carbonyl 
cyanide m -chlorophenylhydrazone (CC CP) w hich  inactivated the pum p by  dissipating 
m em brane potential. N ext, com pounds tested w ere added at the concentration of 100 gM 
and the efflux w as energizing by  autom ated in jection of glucose at a dose of 50 gM . The 
fluorescence intensity  w as m easured in a m icroplate reader (Tecan) w ith  an excitation 
w avelength of Aex =  370 nm  and an em ission w avelength of Aem =  420 nm . Since the 
decrease of fluorescence of 1,2'-dN A w as observed in the presence of compounds tested, the 
pre-energization fluorescence intensity w as adjusted to 100 relative fluorescence units and 
the inhibition efficiency (IE) of each com pound w as calculated according to Equation (2):
IE [%] =  ^  * 100% (2)
Ai2
w here Aq reflects the difference betw een the fluorescence of 1 ,2 '-dN A  in the presence 
and absence of com pound tested after the addition of glucose and Ai2 corresponds to the 
difference betw een the fluorescence of 1,2'-dN A in the presence and absence of compound 
tested before the addition of glucose.
3.4. A D M ET Screening
3.4.1. In Silico Assays
C om puter-aided assays to obtain inform ation about the m etabolism  of com pounds 
w ere perform ed using M etaSite 6 .0 .1  com puter program  provided by M olecular D iscov­
ery Ltd (H ertfordshire, U K ) [50]. D uring calculations M etaSite take into consideration 
enzym e-substrate recognition (therm odynam ic factor) and chem ical transform ation cat­
alyzed by  the enzym es (kinetic factor). The probable sites of m etabolism  w ere obtained 
using various computational m odels, liver, skin, brain, and cytochromes. Compounds 7-23 
w ere analyzed.
3.4.2. In Vitro Assays
The lum inescent C YP3A 4 P450-G lo™  assay w as carried out according to a protocol 
described previously (Prom ega, M adison, W I, U SA ) [51]. The reference com pound ke- 
toconazole w as obtained from  Sigm a-A ldrich. Perform ance of enzym atic reaction w as 
carried ou t in  w hite polystyrene, flat-bottom  N unc™  M icroW ell™  96-W ell M icroplate 
(Therm o Scientific W altham , M A , U SA ) and the result w as m easured w ith  a m icroplate 
reader EnSpire in lum inescence m ode (PerkinElm er, W altham , M A  U SA ). IC 50 values 
w ere calculated  using G raphPad Prism ™  softw are (version 5.01, San  D iego, C A , USA ). 
Com pounds 15 and 19 w ere tested at concentrations from 0.01 gM to 25 gM.
4. C onclu sions
The series of seventeen 5-arylideneim idazolone (7-21) or 5-arylidenethiazolone (22, 
23) derivatives w ith potential antibiotic adjuvant activity in both, Gram -positive and G ram ­
negative bacteria, w as obtained in 3- or 4-step  synthesis. These com pounds contain  a 
m orpholine m oiety at position 2 (7-13, 22, 23) or 3 (14-21). X-ray crystallographic studies 
for one member (7) provided an insight into structural properties of this group, confirming 
the expected Z -configuration for the 5-arylidene substituent. Two of the com pounds, 
nam ely 10 and 15, dem onstrated a significant reduction of oxacillin  MIC in M RSA 19449 
strain. Furthermore, compounds 14-16  proved significant activity in various M RSA strains 
w ith  oxacillin, and even am picillin  in  the case o f com pound 15. The lack  of ad juvant 
activity in any susceptible strain suggests a m olecular m echanism  involving an interaction 
of the com pound w ith  PBP2a. M oreover, m olecular m odeling studies have show n that 
binding at the allosteric site of PBP2a is the m ost probable m echanism  of the ad juvant 
action observed in M RSA  strains. Although none of the com pounds significantly reduced 
MIC values of antibiotics in K. aerogenes strains, several of them exerted a potent 1,2'-dN A 
efflux inhibition (up to 90 % for com pound 19) in the RTE assay. A  recent study has 
analyzed the m olecular and kinetic, e.g., accum ulation and efflux, param eters of various 
fluoroquinolone efflux in E. coli expressing different levels of AcrAB [52] . The efflux index 
(SICAR: Structure Intracellular Concentration A ctivity Relationship) determ ined for each 
fluoroquinolone clearly  dem onstrates the key role of antibiotic side chains and internal 
residues of AcrB in the transporter affinity and in the efficiency of drug translocation across 
the expel channel [52]. C onsistently, the ad juvant potential reflects the strength of the 
affinity A crB-substrate and depends on the m olecular interaction betw een the partners, 
e.g., A crB-antibiotic and A crB-adjuvant. This suggests potential efflux pum p inhibitory 
(EPI) properties for these 5-arylideneim idazolones.
Sum m ing up, the com prehensive SA R  analysis perform ed points out com pound 15 
as the m ost prom ising due to the ability to enhance both, oxacillin , and am picillin , in 
various M RSA strains, and also thanks to its EPI properties. Additionally, this com pound 
show s good drug-like properties in the w ater solubility and in vitro D D I assays. Based 
on the results obtained, the p -phenylbenzylidene derivative 15 exhibits outstanding M DR- 
reversal and drug-like properties and is open to further m odifications in the search for 
new  and versatile agents to overcom e bacterial M D R, especially  in  G ram -positive and 
G ram -negative pathogens.
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14-16 on the susceptibility of S. aureus MM-O021 and R45-CC45 strains to ampicillin. Table S7. 
Effect of compounds 14-16 on the susceptibility of S. aureus MM-O058, MM-N072, and USA300 
LAC strains to ampicillin. Table S8 . Effect of compounds 14-16 on the susceptibility of S. aureus 
5328, LG-N017, and R46-CC22 strains to ampicillin. Table S9. Effect of compounds 14-16 on the 
susceptibility of S. aureus COL and Mu50 strains to ampicillin. Table S10. Effect of compounds 
14-16 on the susceptibility of S. aureus Mu50 strain to vancomycin. Table S11. Effect of compounds 
14-16 on the susceptibility of S. aureus USA300 LAC, R46-CC22, and Mu50 strains to ciprofloxacin. 
Table S12. Effect of compounds 14-16 on the susceptibility of S. aureus MM-O058, MM-N072, and 
LG-N017 strains to erythromycin. Table S13. Effect of compounds 14-16 on the susceptibility of S. 
aureus MM-O021 and USA300 LAC strains to erythromycin. Table S14. Effect of compounds 14-16 
on the susceptibility of S. aureus 53284 and Mu50 strains to erythromycin. Table S15. Antibacterial 
activity of compounds 7-15,17-19, 21-23 against K. aerogenes strain (EA 289). Table S16. Effect of 
compounds 7-15,17-19, 21-23 on the susceptibility of K.aerogenes strain (EA 289) to doxycycline and
erythromycin. Table S17. Effect of compounds 7,12-16,19-20 on the susceptibility of K. aerogenes 
strains to doxycycline, chloramphenicol, norfloxacin, and erythromycin. Results for compounds 16 
and 20 were already published [1]. Table S18. Results of absorbance used for estimation of water 
solubility of tested compounds (9-12, 15, 19). Table S19. Results of chosen compounds (9-12, 15, 
19) stability in acidic conditions. Table S20. Results of chosen compounds (9-12,15,19) stability in 
basic conditions. Figure S1. Docking results to the active site of PBP2a; a) green: 10, orange: 15, 
magenta: 16, cyan: 14; b) green: 7, orange: 8, magenta: 9, cyan: 11; c) green: 12, orange: 13, magenta: 
17, cyan: 18; d) green: 19, orange: 20, magenta: 21, cyan: 22, yellow: 23. Figure S2. Docking results of 
compounds 7-23 to the allosteric site of PBP2a; a) green: 10, orange: 15, magenta: 16, cyan: 14; b) 
green: 7, orange: 8, magenta: 9, cyan: 11; c) green: 12, orange: 13, magenta: 17, cyan: 18; d) green: 
19, orange: 20, magenta: 21, cyan: 22, yellow: 23. Figure S3. Ligand-protein interaction diagrams 
obtained during molecular dynamic simulations for compounds 14-16 in the active site. Figure S4. 
Ligand-protein interaction diagrams obtained during molecular dynamic simulations for compounds 
14-16 in the allosteric site. Figure S5. Results for CYP3A4 metabolism of compound 15 from in silico 
assay (5 most possible metabolites). Figure S6. Results for CYP3A4 metabolism of compound 19 
from in silico assay (5 most possible metabolites).
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